Financials in USD. Standardized financial statements.
A compact view of how HOOKIPA Pharma Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $9.70M | $43.95M | $20.13M | $14.25M | $18.45M | $19.58M | $11.94M | $7.63M | $0 |
| Revenue Growth? | -77.9% | +118.3% | +41.3% | -22.8% | -5.8% | +64.0% | +56.5% | 0.0% | 0.0% |
| Cost of Revenue? | $682,000 | $2.75M | $3.55M | $3.60M | $4.64M | $53.13M | $46.31M | $21.96M | $398,000 |
| Gross Profit? | $9.02M | $41.19M | $16.58M | $10.65M | $13.81M | -$33.55M | -$34.37M | -$14.34M | -$398,000 |
| Gross Margin? | +93.0% | +93.7% | +82.4% | +74.7% | +74.8% | -171.3% | -287.8% | -187.9% | 0.0% |
| Operating Expenses? | $45.59M | $28.27M | $117.82M | $83.80M | $95.48M | $19.74M | $63.03M | $23.20M | $12.09M |
| Operating Income? | -$36.57M | -$51.45M | -$97.69M | -$73.16M | -$81.67M | -$53.28M | -$51.09M | -$21.18M | -$14.16M |
| EBITDA? | -$35.89M | -$40.85M | -$77.34M | -$60.40M | -$70.13M | -$39.15M | -$39.09M | -$14.79M | -$13.76M |
| Income Before Tax | -$13.84M | -$43.61M | -$81.21M | -$64.92M | -$75.67M | -$44.08M | -$43.04M | -$16.21M | -$12.72M |
| Income Tax Expense | $1,000 | -$106,000 | $368,000 | $0 | $0 | $0 | $0 | $24,000 | $4,000 |
| Net Income? | -$13.84M | -$43.50M | -$81.58M | -$64.92M | -$75.67M | -$44.08M | -$43.04M | -$16.24M | -$12.72M |
| EPS? | $-1.09 | $-3.47 | $-8.63 | $-9.91 | $-23.04 | $-16.93 | $-24.10 | $-177.58 | $-139.54 |
| Diluted EPS? | $-1.09 | $-3.47 | $-8.63 | $-9.91 | $-23.04 | $-16.93 | $-24.10 | $-177.57 | $-139.54 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality